Jazz Pharmaceuticals JAZZ Stock
Jazz Pharmaceuticals Price Chart
Jazz Pharmaceuticals JAZZ Financial and Trading Overview
| Jazz Pharmaceuticals stock price | 234.12 USD |
| Previous Close | 230.93 USD |
| Open | 234.13 USD |
| Bid | 216.24 USD x 200 |
| Ask | 254.63 USD x 200 |
| Day's Range | 232.83 - 237.6 USD |
| 52 Week Range | 105 - 243.32 USD |
| Volume | 355.75K USD |
| Avg. Volume | 915.51K USD |
| Market Cap | 14.69B USD |
| Beta (5Y Monthly) | 0.274 |
| PE Ratio (TTM) | 1951.1667 |
| EPS (TTM) | 0.12 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 253.21 USD |
JAZZ Valuation Measures
| Enterprise Value | 17.03B USD |
| Trailing P/E | 1951.1667 |
| Forward P/E | 9.098974 |
| PEG Ratio (5 yr expected) | 0.96 |
| Price/Sales (ttm) | 3.309674 |
| Price/Book (mrq) | 3.2391226 |
| Enterprise Value/Revenue | 3.837 |
| Enterprise Value/EBITDA | 8.481 |
Trading Information
Jazz Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.274 |
| 52-Week Change | 112.25% |
| S&P500 52-Week Change | 27.18% |
| 52 Week High | 243.32 USD |
| 52 Week Low | 105 USD |
| 50-Day Moving Average | 210.69 USD |
| 200-Day Moving Average | 169.11 USD |
JAZZ Share Statistics
| Avg. Volume (3 month) | 915.51K USD |
| Avg. Daily Volume (10-Days) | 891.15K USD |
| Shares Outstanding | 62.74M |
| Float | 60.8M |
| Short Ratio | 4.89 |
| % Held by Insiders | 3.01% |
| % Held by Institutions | 108.59% |
| Shares Short | 4.85M |
| Short % of Float | 8.89% |
| Short % of Shares Outstanding | 7.72% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0.66% |
| Operating Margin (ttm) | 23.51% |
| Gross Margin | 91.50% |
| EBITDA Margin | 45.24% |
Management Effectiveness
| Return on Assets (ttm) | 6.92% |
| Return on Equity (ttm) | 0.67% |
Income Statement
| Revenue (ttm) | 4.44B USD |
| Revenue Per Share (ttm) | 72.52 USD |
| Quarterly Revenue Growth (yoy) | 19.10% |
| Gross Profit (ttm) | 4.06B USD |
| EBITDA | 2.01B USD |
| Net Income Avi to Common (ttm) | 29.45M USD |
| Diluted EPS (ttm) | 0.12 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.87B USD |
| Total Cash Per Share (mrq) | 45.81 USD |
| Total Debt (mrq) | 5.42B USD |
| Total Debt/Equity (mrq) | 119.52 USD |
| Current Ratio (mrq) | 2.04 |
| Book Value Per Share (mrq) | 72.285 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 1.33B USD |
| Levered Free Cash Flow (ttm) | 1.34B USD |
Profile of Jazz Pharmaceuticals
| Country | United States |
| State | N/A |
| City | Dublin |
| Address | Waterloo Exchange |
| ZIP | D04 E5W7 |
| Phone | 353 1 634 7800 |
| Website | https://www.jazzpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 2890 |
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Q&A For Jazz Pharmaceuticals Stock
What is a current JAZZ stock price?
Jazz Pharmaceuticals JAZZ stock price today per share is 234.12 USD.
How to purchase Jazz Pharmaceuticals stock?
You can buy JAZZ shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Jazz Pharmaceuticals?
The stock symbol or ticker of Jazz Pharmaceuticals is JAZZ.
Which industry does the Jazz Pharmaceuticals company belong to?
The Jazz Pharmaceuticals industry is Biotechnology.
How many shares does Jazz Pharmaceuticals have in circulation?
The max supply of Jazz Pharmaceuticals shares is 62.74M.
What is Jazz Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Jazz Pharmaceuticals PE Ratio is 1951.00000000 now.
What was Jazz Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Jazz Pharmaceuticals EPS is 0.12 USD over the trailing 12 months.
Which sector does the Jazz Pharmaceuticals company belong to?
The Jazz Pharmaceuticals sector is Healthcare.
Jazz Pharmaceuticals JAZZ included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26761.07 USD — |
-0.35
|
4.06B USD — | 26554.24 USD — | 26812.16 USD — | — - | 4.06B USD — |
| NYSE Arca Pharmaceutical Index DRG | 1167.73 USD — |
+3.6
|
— — | 1127.15 USD — | 1167.88 USD — | — - | — — |
| US Tech Biotechnology Total Retu XNBI | 6498.86 USD — |
+2.59
|
— — | 6402.05 USD — | 6510.05 USD — | — - | — — |
| US Tech US Smart Pharmaceuticals NQSSPH | 1880.59 USD — |
+2.61
|
— — | 1849.37 USD — | 1886.25 USD — | — - | — — |
| US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG | 4059.8 USD — |
+0.14
|
— — | 4012.43 USD — | 4071.15 USD — | — - | — — |
| US Tech Next Generation 100 Inde NGX | 1838.96 USD — |
+0.2
|
— — | 1816.99 USD — | 1848.21 USD — | — - | — — |
| US Tech Biotechnology NBI | 5953.75 USD — |
+2.52
|
— — | 5868.75 USD — | 5967.75 USD — | — - | — — |
| US Tech Health Care IXHC | 1159.84 USD — |
+2.32
|
— — | 1146.48 USD — | 1165.81 USD — | — - | — — |
| US Tech Composite Total Return XCMP | 33000.65 USD — |
-0.31
|
— — | 32740.79 USD — | 33058.74 USD — | — - | — — |
| US Tech Global Select Market Com NQGS | 13132.16 USD — |
-0.37
|
— — | 13032.51 USD — | 13155.02 USD — | — - | — — |
| US Tech DM Ex Japan Large Mid Ca NQDMXJPLMAUD | 2100.38 AUD 1390.15 USD |
<0.01
|
— — | 2100.38 AUD 1390.15 USD | 2100.38 AUD 1390.15 USD | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}


